Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Transparency notification - FMR LLC reaches 10% threshold

Posted on: 12 Oct 16

MECHELEN, Belgium, Oct. 12, 2016 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Fidelity Management & Research (FMR) LLC.

Pursuant to Belgian transparency legislation[1], Galapagos received a transparency notification on 7 October 2016 from FMR LLC, who notified that it holds 4,616,982 of Galapagos' voting rights, consisting of shares (4,580,182) and equivalent financial instruments (36,800), through its subsidiary undertakings Fidelity Management & Research Company and FMR Co., Inc. This represents 10% of Galapagos' currently outstanding 46,169,828 shares, and is an increase compared to FMR LLC's previous transparency notification of 19 May 2015. FMR LLC reached the 10% threshold of Galapagos' voting rights by acquiring additional voting securities on 3 October 2016. The full transparency notice is available on the Galapagos website.

About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises a pipeline of Phase 3, Phase 2, Phase 1, pre-clinical, and discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. We have discovered and developed filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the world. Galapagos is focused on the development and commercialization of novel medicines that will improve people's lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 460 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. More information at


Investors: Media:
Elizabeth Goodwin Evelyn Fox
VP IR & Corporate
+1 781 460 1784
Director Communications

+31 6 53 591 999

Paul van der Horst
Director IR & Business
+31 6 53 725 199  

Forward-looking statements
This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.

[1]     Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market.

Transparency notification FMR


Last updated on: 13/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.